All In Biotech

Drug Trial Radar · NCT05221008

A Trial of SHR6508 in Secondary Hyperparathyroidism

Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis

Last checked: Nov 19, 2026Latest source record: Aug 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Mar 10, 2022

Primary completion

Jul 7, 2023

Study completion Aug 2, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the tolerability, pharmacokinetics and pharmacodynamics of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis

Conditions

  • Secondary Hyperparathyroidism

Interventions

  • SHR6508;PlaceboDrug

    Group A:SHR6508 low dose

  • SHR6508;PlaceboDrug

    Group B:SHR6508 medium dose

  • SHR6508;PlaceboDrug

    Group C:SHR6508 high dose

  • SHR6508;PlaceboDrug

    Group D:SHR6508 high dose(single dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tmax, Time of maximum observed concentration.Time frame: 0 hour to 43 hours after first dose administration
  2. Cmax, Maximum observed concentration.Time frame: 0 hour to 43 hours after first dose administration
  3. AUC0-t, Area under the concentration-time curve from time zero to the last measurable concentration.Time frame: 0 hour to 43 hours after first dose administration
  4. AUC0-∞, Area under the curve from time 0 extrapolated to infinite timeTime frame: 0 hour to 43 hours after first dose administration
  5. t1/2z, Terminal elimination half-lifeTime frame: 0 hour to 43 hours after first dose administration
  6. CLz, Total Body ClearanceTime frame: 0 hour to 43 hours after first dose administration
  7. Vz, Volume of distribution based on the terminal phaseTime frame: 0 hour to 43 hours after first dose administration
  8. MRT0-t, Mean residence time from time zero to the last measurable concentration.Time frame: 0 hour to 43 hours after first dose administration
  9. MRT0-∞, Mean residence time from time 0 extrapolated to infinite timeTime frame: 0 hour to 43 hours after first dose administration
  10. Cmax,ss : Maximum observed concentration at steady-state.Time frame: Day1-Day29(if reach steady-state)
  11. Cmin,ss : Minimum observed concentration at steady-stateTime frame: Day1-Day29(if reach steady-state)
  12. Cav : Average concentrationTime frame: Day1-Day29(if reach steady-state)
  13. AUC0-t,ss, Area under the concentration-time curve from time zero to the last measurable concentration at steady-state.Time frame: Day1-Day29(if reach steady-state)
  14. AUC0-∞,ss, Area under the concentration-time curve from time 0 extrapolated to infinite time at steady-state.Time frame: Day1-Day29(if reach steady-state)
  15. Tmax,ss, Time of maximum observed concentration at steady-state.Time frame: Day1-Day29(if reach steady-state)
  16. t1/2z,ss, Terminal elimination half-life at steady-stateTime frame: Day1-Day29(if reach steady-state)
  17. CLss, Total Body Clearance at steady-state.Time frame: Day1-Day29(if reach steady-state)
  18. Vss, Volume of distribution based on the terminal phase at steady-state.Time frame: Day1-Day29(if reach steady-state)
  19. MRT0-∞, Mean residence time from time 0 extrapolated to infinite time.Time frame: Day1-Day29(if reach steady-state)
  20. DF: Degree of FluctuationTime frame: Day1-Day29(if reach steady-state)
  21. Accumulation RatioTime frame: Day1-Day29(if reach steady-state)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.